期刊文献+

高血压合并代谢综合征患者奥美沙坦治疗后剂量依赖性减轻动脉硬化及向心性重构 被引量:4

原文传递
导出
摘要 血管紧张素受体拮抗剂长期治疗是否能够剂量依赖性地重构血管壁一直存在很大争议。该研究为三期、多中心随机双盲平行分组临床试验,采用强制性剂量逐步递增方案(force titration design),纳入133例高血压合并代谢综合征患者随机分配到奥美沙坦20mg(44例)、40 mg(42例)或80 mg(47例)组,1次/d,为期1年。在基线、24周、52周时测定诊室血压、24h动态血压、主动脉僵硬度(颈股动脉脉搏波传导速度)和颈动脉参数。
出处 《中华高血压杂志》 CAS CSCD 北大核心 2014年第9期864-864,共1页 Chinese Journal of Hypertension
  • 相关文献

同被引文献59

  • 1谢维宁,杨钦河,纪桂元.代谢综合征的中医病因病机探讨[J].时珍国医国药,2007,18(3):716-717. 被引量:16
  • 2Marchi-Alves LM, Rigotti AR, Nogueira MS, et al. Metabolic syndrome components in arterial hypertension[J].Rev Esc En- ferm USP,2012,46(6) : 1348- 1353.
  • 3Koprowski P, Kostkiewicz M, Lesniak - Sobelga A. Echocardio graphic assessment of left atrial volume in asymptomatic ambu- latory patients with metabolic syndrome and/or arterial hyperten sion:is it parameter worth into considerate? [J].Przegl Lek, 2012,69(11) : 1199- 1204.
  • 4Morozova TE, Andrushchishina TB, Oshorova SD.Optimisation of arterial hypertension pharmacotherapy in patients with metabolic syndrome; potential of zofenopril[J].Russian Journal of Cardiol- ogy,2011(4) :63- 68.
  • 5Kinoshita S, Ryuzaki M, Sone M, et al. Effectiveness of using long - acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hyperten- sion monitoring by using telemedicine system (FWIYAMA study) [J].Clin Exp Hypertens,2014,36(7):508- 516.
  • 6Murakami K,Wada J,Ogawa D, et al .The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension, Abdominal fat Depot In- tervention Program of Okayama (ADIPO)[J].Diabetes & Vascu- lar Disease Research, 2013,10( 1 ) : 93 - 96.
  • 7Akyurek O,Akbal E, Gunes F, et al .Peroxisome proliferator- activated receptor gamma concentrations in newly diagnosed hypertension patients and the metabolic effects of olmesartan [J].Archives of Medical Research,2014,45(2) :138 - 142.
  • 8Nedogoda SV, Chumachok EV, Ledyaeva AA, et al. Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension[J].Cardiovascular Therapy and Prevention, 2011,10(6) : 24 - 29.
  • 9Oleynikov V, Gusakovskaya L, Matrosova I, et al .Indicators of central pressure and rigidity during the long - term therapy of calcium antagonists in patients with metabolic syndrome and hy- pertension[J].Atherosclerosis, 2014,235(2) : E265.
  • 10Ueno N,Satou Y.The enhanced effect of atenolol on hyperten sion in metabolic syndrome[J].Metab Syndr Relat Disord, 2011,9(5):369- 373.

引证文献4

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部